What is OncoMethylome Sciences?
OncoMethylome Sciences is a bio-tech company dedicated to advancing cancer care through the development of DNA gene methylation tests. These cutting-edge diagnostic solutions are designed for early cancer detection and to guide personalized treatment decisions, assisting physicians in identifying cancer at its nascent stages and predicting patient responses to therapy or the probability of recurrence. The company's mission is to enhance cancer treatment outcomes by providing novel diagnostic tools to healthcare professionals and institutions.
How much funding has OncoMethylome Sciences raised?
OncoMethylome Sciences has raised a total of $21.9M across 2 funding rounds:
Share Placement
$12.1M
Grant
$9.7M
Share Placement (2007): $12.1M, investors not publicly disclosed
Grant (2009): $9.7M, investors not publicly disclosed
What's next for OncoMethylome Sciences?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for OncoMethylome Sciences. This capital infusion is expected to accelerate the company's research and development efforts, potentially expanding its product pipeline and market reach. The focus on early detection and personalized treatment aligns with the growing demand for precision medicine, positioning OncoMethylome Sciences to play a crucial role in shaping the future of oncology diagnostics. Future strategic partnerships and further financing rounds may be anticipated as the company scales its operations and commercializes its innovative diagnostic solutions.
See full OncoMethylome Sciences company page
